FDA OKs Epclusa, First Drug for All Major Forms of HCV

June 28, 2016

(Medscape) – The US Food and Drug Administration (FDA) has approved the combination drug of sofosbuvir and velpatasvir (Epclusa, Gilead Sciences) for adults with chronic hepatitis C virus (HCV) infection, the first one to treat all six major genotypes of the infection, the agency announced today. The new drug’s broad coverage could make it a one-size-fits-all therapy suitable for primary care. Gilead Sciences President and CEO John Gilliland said in a news release that sofosbuvir/velpatasvir could eliminate the need for genotype testing, “which can be a barrier to treatment in certain resource-constrained settings.”